1. Generics Bulletin
  2. >>Business

Mayne Completes Divestment Of US Generics To Dr Reddy’s

Indian Industry Giant Takes Control Of Australian Firm’s Generics Business

 
• By Dave Wallace

Mayne Pharma and Dr Reddy’s have announced the completion of a deal that will see the Indian company take over the Australian firm’s US generics business.

Completed word stamp green
Mayne and Dr Reddy’s have completed their deal • Source: Shutterstock

Mayne Pharma and Dr Reddy’s have promised to work together to ensure “a smooth transition for customers” after the Australian firm completed the divestment of its US generics business to the Indian player in a deal worth at least $90m, plus potentially up to $15m in contingent milestone payments.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.